Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 3

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 3
---
 Canada: +1 857-999-9155 (standard rates apply)

Conference ID: 9201360#</div>

FutureTech is a blank check company formed under the laws of the State of Delaware for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses, which we refer to as a “business combination.”

At the Special Meeting, FutureTech stockholders will be asked to consider and vote upon a proposal to approve and adopt the Agreement and Plan of Merger, dated as of September 16, 2024 (the “Merger Agreement”), by and among FutureTech, LBI Merger Sub, Inc., a Delaware corporation and direct, wholly-owned subsidiary of FutureTech (“Merger Sub”), Longevity Biomedical, Inc., a Delaware corporation (“Longevity”), and Bradford A. Zakes, solely in the capacity as a Seller Representative (the “Seller Representative”), a copy of which is attached to the accompanying proxy statement/prospectus as Annex A(such proposal, the “Business Combination Proposal”).

The board of directors of FutureTech (the “Board”) has unanimously approved the Merger Agreement and the Transactions (as defined below). Pursuant to the Merger Agreement, subject to the terms and conditions set forth therein, the parties thereto will enter into a business combination transaction (the “Business Combination” and together with the other transactions contemplated by the Merger Agreement, the “Transactions”), pursuant to which, among other things, (i) Longevity will consummate Target Acquisitions (as defined below) upon the terms and subject to conditions set forth therein and pursuant to the Target Acquisition Agreements (as defined therein), and (ii) immediately following the consummation of the Target Acquisitions, Longevity will merge with and into Merger Sub (the “Merger”) with Longevity as the surviving company of the Merger. Following the Merger, Longevity will be a wholly-owned subsidiary of FutureTech. At the closing of the Transactions (the “Closing”), FutureTech is expected to change its name to “Longevity Biomedical, Inc.” and FutureTech’s common stock, par value $0.0001 per share (the “FutureTech Common Stock”), is expected to list on the Nasdaq Stock Market LLC (“Nasdaq”) under the ticker symbol “LBIO.” The date on which the Closing actually occurs is hereinafter referred to as the “Closing Date.” It is a